Sugi Predict

Sugi Predict / Compounds / SCHEMBL484670

SCHEMBL484670

SCHEMBL484670

COC(=O)c1c(Cl)cccc1CBr

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ CA14 Q9ULX7 1/20 0.47
▸ POLB P06746 2/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ GAA P10253 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ TSHR P16473 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ FEN1 P39748 1/20 0.41
▸ NR4A2 P43354 3/20 0.41
▸ TDP1 Q9NUW8 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26622086 0.93 LMNA (0.47) LMNASMN1; SMN2CA12CA1CA2
SCHEMBL9544732 0.88 CA12 (0.55) LMNASMN1; SMN2CA12CA1CA2
SCHEMBL28802457 0.87 LMNA (0.47) LMNASMN1; SMN2CA12CA1CA2
SCHEMBL5256419 0.85 LMNA (0.50) LMNASMN1; SMN2CA12CA1CA2
SCHEMBL4996201 0.85 LMNA (0.50) LMNASMN1; SMN2CA12CA1CA2
SCHEMBL5256415 0.85 LMNA (0.50) LMNASMN1; SMN2CA12CA1CA2
SCHEMBL19879735 0.83 LMNA (0.49) LMNASMN1; SMN2CA12CA1CA2
SCHEMBL19731335 0.83 LMNA (0.49) LMNASMN1; SMN2CA12CA1CA2
SCHEMBL19731338 0.83 CA12 (0.50) LMNASMN1; SMN2CA12CA1CA2
SCHEMBL30296784 0.82 LMNA (0.48) LMNASMN1; SMN2CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922387-B Heterocyclic inhibitors of ERK1 and ERK2 and their use in cancer treatment 阿沙纳生物科学公司 2024-11-22 — — CN disclosed
EP-4426681-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS Sitryx Therapeutics Limited (GB) 2024-09-11 — — EP disclosed
CN-118317951-A Phthalazine derivatives as pyruvate kinase modulators 西特瑞治疗有限公司 2024-07-09 — — CN disclosed
US-12029739-B2 SHP2 inhibitor and use thereof KANAPH THERAPEUTICS INC. (KR) 2024-07-09 — — US disclosed
US-11925629-B2 Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer ASANA BIOSCIENCES, LLC (US) 2024-03-12 — — US disclosed
CN-113200961-B Heterocyclic inhibitors of ERK1 and ERK2 and their use in cancer treatment 阿沙纳生物科学公司 2023-12-22 — — CN disclosed
EP-3307727-B1 HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER ASANA BIOSCIENCES LLC (US) 2023-10-04 — — EP disclosed
EP-3307727-B1 HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER ASANA BIOSCIENCES LLC (US) 2023-10-04 — — EP disclosed
WO-2023079294-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2023-05-11 — — WO disclosed
WO-2023079294-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2023-05-11 — — WO disclosed
WO-2006113140-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM ELAN PHARMACEUTICALS, INC. (US) 2006-10-26 — — WO disclosed
WO-2006077419-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2006077414-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2006077414-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 — — WO disclosed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 — — WO disclosed
CN-1240684-C Dibenzocycloheptene compound UBE INDUSTRIES (JP) 2006-02-08 — — CN disclosed
CN-1531528-A Dibenzocycloheptene compound ��˲���ʽ���� 2004-09-22 — — CN disclosed
US-20040180884-A1 Dibenzocycloheptene compound UBE INDUSTRIES, LTD. (JP) 2004-09-16 — — US disclosed
EP-1408033-A1 DIBENZOCYCLOHEPTENE COMPOUND Ube Industries, Ltd. (JP) 2004-04-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180884-A1 Dibenzocycloheptene compound LTB4R2, LTA4H, LTC4S LMNA 4347/4885SMN1; SMN2 3578/4885CA12 2786/4885
US-11925629-B2 Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer KRAS, NRAS, RAF1 LMNA 3393/4885SMN1; SMN2 1201/4885CA12 4256/4885
US-12029739-B2 SHP2 inhibitor and use thereof PTPN1, PTPN5, PTPN2 LMNA 4782/4885SMN1; SMN2 2643/4885CA12 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.